-
Product Insights
New![]()
Net Present Value Model: Otsuka Holdings Co Ltd’s Centanafadine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Otsuka Holdings Co Ltd’s (Deudextromethorphan hydrobromide + Quinidine sulfate)
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Otsuka Holdings Co Ltd's (Deudextromethorphan hydrobromide + Quinidine sulfate) Drug Details: AVP-786 is under development for the treatment of agitation associated with dementia of...
-
Track & Monitor
New![]()
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
New![]()
Net Present Value Model: Processa Pharmaceuticals Inc’s Roducitabine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Sector Analysis
New![]()
Heart Failure in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Heart Failure Market Report Overview The heart failure market size across the 7MM was valued at $31.9 billion in 2022 and is expected to achieve a CAGR of more than 5% during 2022-2032. The 7MM includes the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. GlobalData expects uptake of SGLT2 inhibitors and three first-in-class drugs to be the strongest driver of the total heart failure markets in the 7MM. Heart Failure Market Outlook, 2022-2032 ($ Billion) Buy...
-
Case Studies
![]()
Non-Alcoholic Beverages Packaging Opportunities – New Packaging Formats and Value-added Features
Category Packaging Opportunities: Non-Alcoholic Beverages explores new packaging formats and value-added features in the non-alcoholic beverages categories, using examples from GlobalData's Pack-Track innovation tool. With a huge and varied range of products on the retail shelf, it can be difficult for brand owners to offer something unique to consumers. Packaging is a key element that can provide differentiation and important added-value benefits. By using packaging to improve convenience and functionality it is possible to adapt to changing consumer lifestyles. Packaging...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Brexpiprazole in Post-Traumatic Stress Disorder (PTSD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brexpiprazole in Post-Traumatic Stress Disorder (PTSD) Drug Details: Brexpiprazole (Rexulti, Rxulti) is a quinolinone derivative,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Brexpiprazole in Autism Spectrum Disorder (ASD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brexpiprazole in Autism Spectrum Disorder (ASD) Drug Details: Brexpiprazole (Rexulti, Rxulti) is a quinolinone derivative,...
-
Product Insights
![]()
Polycystic Kidney Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Polycystic Kidney Disease Clinical Trials Market Report Overview The polycystic kidney disease clinical trial market research report provides an overview of the polycystic kidney disease clinical trials scenario. The report provides top-line data relating to the clinical trials on polycystic kidney disease. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tesidolumab in Posterior Uveitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tesidolumab in Posterior Uveitis Drug Details: Tesidolumab (LFG-316) is under development for the treatment of...
-
Product Insights
![]()
Internet of Things in healthcare: Body area network (BAN)
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the healthcare industry’s Body area network (BAN) within Internet of Things innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts...
-
Track & Monitor
![]()
Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen receptor (CAR) T-cell therapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
![]()
Autism Spectrum Disorder (ASD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Autism Spectrum Disorder (ASD) Clinical Trials Market Report Overview The Autism Spectrum Disorder (ASD) clinical trial market research report provides an overview of the Autism Spectrum Disorder (ASD) clinical trials scenario. This report provides top-line data relating to the clinical trials on ASD and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rebamipide SR in Gastritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Rebamipide SR in GastritisDrug Details:Rebamipide SR is under development for the treatment of acute and chronic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NO-13065 in Obesity
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NO-13065 in Obesity Drug Details: NO-13065 is under development for the treatment of obesity....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7200394 in Macular Edema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.RO-7200394 in Macular EdemaDrug Details:RO-7200394 is under development for the treatment of macular edema secondary to...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YL-202 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. YL-202 in Non-Small Cell Lung Cancer Drug Details: YL-202 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LPCN-1154 in Post Partum Depression (Maternal Depression / Postnatal Depression)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Post Partum Depression (Maternal Depression / Postnatal Depression) Drug Details: Brexanolone is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OPS-2071 in Irritable Bowel Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. OPS-2071 in Irritable Bowel Syndrome Drug Details: OPS-2071 is under development for diarrhea-predominant irritable bowel syndrome of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine For Oncology in Brain Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Vaccine For Oncology in Brain TumorDrug Details:Plasmodium immunotherapy is under development for the treatment of non-small...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.